Safety of Effivia®, a Bevacizumab Biosimilar

Inclusion Criteria:

• Male and female patients, 18 years and older.

• Patients with metastatic colorectal cancer,unresectable, locally advanced, recurrentor metastatic non-squamous non-small cell lung cancer, metastatic renal cellcarcinoma, persistent, recurrent, or metastatic cervical cancer, or epithelialovarian, fallopian tube, or primary peritoneal cancer naive to bevacizumab therapy (Effivia®).

• Provide written informed consent.

Exclusion Criteria:

• History of recent surgery or wound healing complications.

• History of gastrointestinal perforations or fistula.

• History of renal injury and proteinuria.

• Recent surgical intervention.

• Pregnant or nursing women.

• History of bevacizumab, monoclonal antibodies, or CHO cells-derived productshypersensitivity.

• Other safety concerns or bevacizumab contraindications.